nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—ADRB1—Bromocriptine—type 2 diabetes mellitus	0.395	1	CbGbCtD
Metipranolol—Alprenolol—ADRB3—type 2 diabetes mellitus	0.00358	0.388	CrCbGaD
Metipranolol—Pindolol—ADRB3—type 2 diabetes mellitus	0.00308	0.334	CrCbGaD
Metipranolol—Propranolol—ADRB3—type 2 diabetes mellitus	0.00168	0.182	CrCbGaD
Metipranolol—Asthenia—Nateglinide—type 2 diabetes mellitus	0.00158	0.00365	CcSEcCtD
Metipranolol—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.00158	0.00365	CcSEcCtD
Metipranolol—Oedema—Glipizide—type 2 diabetes mellitus	0.00158	0.00364	CcSEcCtD
Metipranolol—Myalgia—Pioglitazone—type 2 diabetes mellitus	0.00158	0.00364	CcSEcCtD
Metipranolol—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00158	0.00363	CcSEcCtD
Metipranolol—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00158	0.00363	CcSEcCtD
Metipranolol—Cough—Sitagliptin—type 2 diabetes mellitus	0.00157	0.00362	CcSEcCtD
Metipranolol—Angina pectoris—Metformin—type 2 diabetes mellitus	0.00157	0.00361	CcSEcCtD
Metipranolol—Bradycardia—Gliclazide—type 2 diabetes mellitus	0.00157	0.00361	CcSEcCtD
Metipranolol—Discomfort—Pioglitazone—type 2 diabetes mellitus	0.00156	0.0036	CcSEcCtD
Metipranolol—Hypertension—Glimepiride—type 2 diabetes mellitus	0.00156	0.0036	CcSEcCtD
Metipranolol—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00156	0.00358	CcSEcCtD
Metipranolol—Hypertension—Sitagliptin—type 2 diabetes mellitus	0.00156	0.00358	CcSEcCtD
Metipranolol—Rhinitis—Gliclazide—type 2 diabetes mellitus	0.00154	0.00355	CcSEcCtD
Metipranolol—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.00154	0.00354	CcSEcCtD
Metipranolol—Myalgia—Sitagliptin—type 2 diabetes mellitus	0.00153	0.00353	CcSEcCtD
Metipranolol—Anxiety—Glimepiride—type 2 diabetes mellitus	0.00153	0.00353	CcSEcCtD
Metipranolol—Anxiety—Sitagliptin—type 2 diabetes mellitus	0.00153	0.00352	CcSEcCtD
Metipranolol—Discomfort—Sitagliptin—type 2 diabetes mellitus	0.00152	0.00349	CcSEcCtD
Metipranolol—Oedema—Pioglitazone—type 2 diabetes mellitus	0.00151	0.00349	CcSEcCtD
Metipranolol—Rash—Tolazamide—type 2 diabetes mellitus	0.0015	0.00346	CcSEcCtD
Metipranolol—Rash—Chlorpropamide—type 2 diabetes mellitus	0.0015	0.00346	CcSEcCtD
Metipranolol—Atrial fibrillation—Ramipril—type 2 diabetes mellitus	0.00149	0.00344	CcSEcCtD
Metipranolol—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00149	0.00344	CcSEcCtD
Metipranolol—Headache—Tolazamide—type 2 diabetes mellitus	0.00149	0.00344	CcSEcCtD
Metipranolol—Rash—Linagliptin—type 2 diabetes mellitus	0.00149	0.00343	CcSEcCtD
Metipranolol—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.00149	0.00342	CcSEcCtD
Metipranolol—Epistaxis—Valsartan—type 2 diabetes mellitus	0.00148	0.00342	CcSEcCtD
Metipranolol—Visual impairment—Gliclazide—type 2 diabetes mellitus	0.00148	0.00341	CcSEcCtD
Metipranolol—Angina pectoris—Irbesartan—type 2 diabetes mellitus	0.00148	0.0034	CcSEcCtD
Metipranolol—Headache—Linagliptin—type 2 diabetes mellitus	0.00148	0.0034	CcSEcCtD
Metipranolol—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00146	0.00336	CcSEcCtD
Metipranolol—Arthritis—Ramipril—type 2 diabetes mellitus	0.00146	0.00336	CcSEcCtD
Metipranolol—Rash—Acarbose—type 2 diabetes mellitus	0.00144	0.00333	CcSEcCtD
Metipranolol—Dermatitis—Acarbose—type 2 diabetes mellitus	0.00144	0.00332	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Glipizide—type 2 diabetes mellitus	0.00144	0.00332	CcSEcCtD
Metipranolol—Rhinitis—Valsartan—type 2 diabetes mellitus	0.00142	0.00326	CcSEcCtD
Metipranolol—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00142	0.00326	CcSEcCtD
Metipranolol—Nausea—Tolazamide—type 2 diabetes mellitus	0.00142	0.00326	CcSEcCtD
Metipranolol—Dyspnoea—Glipizide—type 2 diabetes mellitus	0.00141	0.00325	CcSEcCtD
Metipranolol—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.00141	0.00324	CcSEcCtD
Metipranolol—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00141	0.00324	CcSEcCtD
Metipranolol—Somnolence—Glipizide—type 2 diabetes mellitus	0.00141	0.00324	CcSEcCtD
Metipranolol—Vision blurred—Glyburide—type 2 diabetes mellitus	0.00141	0.00324	CcSEcCtD
Metipranolol—Rash—Nateglinide—type 2 diabetes mellitus	0.00139	0.00321	CcSEcCtD
Metipranolol—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.00139	0.0032	CcSEcCtD
Metipranolol—Angina pectoris—Losartan—type 2 diabetes mellitus	0.00139	0.0032	CcSEcCtD
Metipranolol—Anxiety—Bromocriptine—type 2 diabetes mellitus	0.00138	0.00319	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Pioglitazone—type 2 diabetes mellitus	0.00138	0.00318	CcSEcCtD
Metipranolol—Bronchitis—Losartan—type 2 diabetes mellitus	0.00137	0.00316	CcSEcCtD
Metipranolol—Nausea—Acarbose—type 2 diabetes mellitus	0.00136	0.00313	CcSEcCtD
Metipranolol—Dyspnoea—Pioglitazone—type 2 diabetes mellitus	0.00135	0.00311	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Sitagliptin—type 2 diabetes mellitus	0.00134	0.00309	CcSEcCtD
Metipranolol—Acute coronary syndrome—Irbesartan—type 2 diabetes mellitus	0.00133	0.00307	CcSEcCtD
Metipranolol—Oedema—Bromocriptine—type 2 diabetes mellitus	0.00133	0.00307	CcSEcCtD
Metipranolol—Myocardial infarction—Irbesartan—type 2 diabetes mellitus	0.00133	0.00305	CcSEcCtD
Metipranolol—Dyspnoea—Glimepiride—type 2 diabetes mellitus	0.00132	0.00303	CcSEcCtD
Metipranolol—Conjunctivitis—Irbesartan—type 2 diabetes mellitus	0.00131	0.00303	CcSEcCtD
Metipranolol—Tension—Gliclazide—type 2 diabetes mellitus	0.00131	0.00303	CcSEcCtD
Metipranolol—Somnolence—Glimepiride—type 2 diabetes mellitus	0.00131	0.00302	CcSEcCtD
Metipranolol—Nausea—Nateglinide—type 2 diabetes mellitus	0.00131	0.00302	CcSEcCtD
Metipranolol—Bradycardia—Metformin—type 2 diabetes mellitus	0.00131	0.00302	CcSEcCtD
Metipranolol—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.00131	0.00301	CcSEcCtD
Metipranolol—Nervousness—Gliclazide—type 2 diabetes mellitus	0.0013	0.003	CcSEcCtD
Metipranolol—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.0013	0.00299	CcSEcCtD
Metipranolol—Rhinitis—Metformin—type 2 diabetes mellitus	0.00129	0.00297	CcSEcCtD
Metipranolol—Epistaxis—Irbesartan—type 2 diabetes mellitus	0.00128	0.00294	CcSEcCtD
Metipranolol—Myalgia—Glyburide—type 2 diabetes mellitus	0.00127	0.00292	CcSEcCtD
Metipranolol—Conjunctivitis—Losartan—type 2 diabetes mellitus	0.00124	0.00285	CcSEcCtD
Metipranolol—Bradycardia—Irbesartan—type 2 diabetes mellitus	0.00124	0.00285	CcSEcCtD
Metipranolol—Rhinitis—Irbesartan—type 2 diabetes mellitus	0.00122	0.0028	CcSEcCtD
Metipranolol—Oedema—Glyburide—type 2 diabetes mellitus	0.00122	0.0028	CcSEcCtD
Metipranolol—Rash—Repaglinide—type 2 diabetes mellitus	0.00121	0.00278	CcSEcCtD
Metipranolol—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.0012	0.00277	CcSEcCtD
Metipranolol—Epistaxis—Losartan—type 2 diabetes mellitus	0.0012	0.00277	CcSEcCtD
Metipranolol—Headache—Repaglinide—type 2 diabetes mellitus	0.0012	0.00276	CcSEcCtD
Metipranolol—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00119	0.00275	CcSEcCtD
Metipranolol—Angina pectoris—Ramipril—type 2 diabetes mellitus	0.00119	0.00275	CcSEcCtD
Metipranolol—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.00119	0.00273	CcSEcCtD
Metipranolol—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.00118	0.00273	CcSEcCtD
Metipranolol—Palpitations—Gliclazide—type 2 diabetes mellitus	0.00118	0.00273	CcSEcCtD
Metipranolol—Bronchitis—Ramipril—type 2 diabetes mellitus	0.00118	0.00271	CcSEcCtD
Metipranolol—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.00117	0.0027	CcSEcCtD
Metipranolol—Cough—Gliclazide—type 2 diabetes mellitus	0.00117	0.00269	CcSEcCtD
Metipranolol—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00117	0.00268	CcSEcCtD
Metipranolol—Vision blurred—Valsartan—type 2 diabetes mellitus	0.00116	0.00267	CcSEcCtD
Metipranolol—Hypertension—Gliclazide—type 2 diabetes mellitus	0.00116	0.00266	CcSEcCtD
Metipranolol—Rhinitis—Losartan—type 2 diabetes mellitus	0.00115	0.00264	CcSEcCtD
Metipranolol—Vision blurred—Orlistat—type 2 diabetes mellitus	0.00115	0.00264	CcSEcCtD
Metipranolol—Myalgia—Gliclazide—type 2 diabetes mellitus	0.00114	0.00263	CcSEcCtD
Metipranolol—Rash—Rosiglitazone—type 2 diabetes mellitus	0.00114	0.00262	CcSEcCtD
Metipranolol—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00114	0.00262	CcSEcCtD
Metipranolol—Anxiety—Gliclazide—type 2 diabetes mellitus	0.00114	0.00262	CcSEcCtD
Metipranolol—Nausea—Repaglinide—type 2 diabetes mellitus	0.00114	0.00262	CcSEcCtD
Metipranolol—Asthenia—Glipizide—type 2 diabetes mellitus	0.00113	0.00261	CcSEcCtD
Metipranolol—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00113	0.00261	CcSEcCtD
Metipranolol—Discomfort—Gliclazide—type 2 diabetes mellitus	0.00113	0.00259	CcSEcCtD
Metipranolol—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00112	0.00257	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.00111	0.00255	CcSEcCtD
Metipranolol—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00109	0.0025	CcSEcCtD
Metipranolol—Palpitations—Valsartan—type 2 diabetes mellitus	0.00109	0.0025	CcSEcCtD
Metipranolol—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00109	0.0025	CcSEcCtD
Metipranolol—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.00108	0.0025	CcSEcCtD
Metipranolol—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00108	0.0025	CcSEcCtD
Metipranolol—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.00108	0.00248	CcSEcCtD
Metipranolol—Palpitations—Orlistat—type 2 diabetes mellitus	0.00107	0.00247	CcSEcCtD
Metipranolol—Cough—Valsartan—type 2 diabetes mellitus	0.00107	0.00247	CcSEcCtD
Metipranolol—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00107	0.00247	CcSEcCtD
Metipranolol—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.00107	0.00247	CcSEcCtD
Metipranolol—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.00106	0.00244	CcSEcCtD
Metipranolol—Cough—Orlistat—type 2 diabetes mellitus	0.00106	0.00244	CcSEcCtD
Metipranolol—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00106	0.00244	CcSEcCtD
Metipranolol—Vision blurred—Metformin—type 2 diabetes mellitus	0.00106	0.00243	CcSEcCtD
Metipranolol—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00106	0.00243	CcSEcCtD
Metipranolol—Myalgia—Valsartan—type 2 diabetes mellitus	0.00105	0.00241	CcSEcCtD
Metipranolol—Dizziness—Glipizide—type 2 diabetes mellitus	0.00105	0.00241	CcSEcCtD
Metipranolol—Anxiety—Valsartan—type 2 diabetes mellitus	0.00104	0.0024	CcSEcCtD
Metipranolol—Tension—Irbesartan—type 2 diabetes mellitus	0.00104	0.00239	CcSEcCtD
Metipranolol—Myalgia—Orlistat—type 2 diabetes mellitus	0.00103	0.00238	CcSEcCtD
Metipranolol—Anxiety—Orlistat—type 2 diabetes mellitus	0.00103	0.00238	CcSEcCtD
Metipranolol—Epistaxis—Ramipril—type 2 diabetes mellitus	0.00103	0.00237	CcSEcCtD
Metipranolol—Nervousness—Irbesartan—type 2 diabetes mellitus	0.00103	0.00237	CcSEcCtD
Metipranolol—Discomfort—Orlistat—type 2 diabetes mellitus	0.00102	0.00236	CcSEcCtD
Metipranolol—Oedema—Valsartan—type 2 diabetes mellitus	0.001	0.00231	CcSEcCtD
Metipranolol—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.001	0.00231	CcSEcCtD
Metipranolol—Rash—Glipizide—type 2 diabetes mellitus	0.000997	0.0023	CcSEcCtD
Metipranolol—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000996	0.0023	CcSEcCtD
Metipranolol—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000996	0.00229	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000996	0.00229	CcSEcCtD
Metipranolol—Oedema—Orlistat—type 2 diabetes mellitus	0.000992	0.00229	CcSEcCtD
Metipranolol—Headache—Glipizide—type 2 diabetes mellitus	0.000991	0.00228	CcSEcCtD
Metipranolol—Palpitations—Metformin—type 2 diabetes mellitus	0.00099	0.00228	CcSEcCtD
Metipranolol—Tension—Losartan—type 2 diabetes mellitus	0.000976	0.00225	CcSEcCtD
Metipranolol—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000976	0.00225	CcSEcCtD
Metipranolol—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000974	0.00224	CcSEcCtD
Metipranolol—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000973	0.00224	CcSEcCtD
Metipranolol—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000971	0.00224	CcSEcCtD
Metipranolol—Hypertension—Metformin—type 2 diabetes mellitus	0.000967	0.00223	CcSEcCtD
Metipranolol—Nervousness—Losartan—type 2 diabetes mellitus	0.000966	0.00223	CcSEcCtD
Metipranolol—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000955	0.0022	CcSEcCtD
Metipranolol—Myalgia—Metformin—type 2 diabetes mellitus	0.000954	0.0022	CcSEcCtD
Metipranolol—Headache—Pioglitazone—type 2 diabetes mellitus	0.000949	0.00219	CcSEcCtD
Metipranolol—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000944	0.00218	CcSEcCtD
Metipranolol—Discomfort—Metformin—type 2 diabetes mellitus	0.000942	0.00217	CcSEcCtD
Metipranolol—Nausea—Glipizide—type 2 diabetes mellitus	0.000939	0.00216	CcSEcCtD
Metipranolol—Vision blurred—Losartan—type 2 diabetes mellitus	0.000938	0.00216	CcSEcCtD
Metipranolol—Rash—Glimepiride—type 2 diabetes mellitus	0.00093	0.00214	CcSEcCtD
Metipranolol—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00093	0.00214	CcSEcCtD
Metipranolol—Rash—Sitagliptin—type 2 diabetes mellitus	0.000927	0.00214	CcSEcCtD
Metipranolol—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000927	0.00213	CcSEcCtD
Metipranolol—Headache—Glimepiride—type 2 diabetes mellitus	0.000924	0.00213	CcSEcCtD
Metipranolol—Cough—Irbesartan—type 2 diabetes mellitus	0.000923	0.00213	CcSEcCtD
Metipranolol—Headache—Sitagliptin—type 2 diabetes mellitus	0.000922	0.00212	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000915	0.00211	CcSEcCtD
Metipranolol—Oedema—Metformin—type 2 diabetes mellitus	0.000914	0.00211	CcSEcCtD
Metipranolol—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000913	0.0021	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000904	0.00208	CcSEcCtD
Metipranolol—Myalgia—Irbesartan—type 2 diabetes mellitus	0.0009	0.00207	CcSEcCtD
Metipranolol—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000897	0.00207	CcSEcCtD
Metipranolol—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000897	0.00207	CcSEcCtD
Metipranolol—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000895	0.00206	CcSEcCtD
Metipranolol—Somnolence—Valsartan—type 2 diabetes mellitus	0.000893	0.00206	CcSEcCtD
Metipranolol—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000889	0.00205	CcSEcCtD
Metipranolol—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00088	0.00203	CcSEcCtD
Metipranolol—Palpitations—Losartan—type 2 diabetes mellitus	0.000879	0.00203	CcSEcCtD
Metipranolol—Nausea—Glimepiride—type 2 diabetes mellitus	0.000877	0.00202	CcSEcCtD
Metipranolol—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000874	0.00201	CcSEcCtD
Metipranolol—Asthenia—Glyburide—type 2 diabetes mellitus	0.000873	0.00201	CcSEcCtD
Metipranolol—Cough—Losartan—type 2 diabetes mellitus	0.000868	0.002	CcSEcCtD
Metipranolol—Oedema—Irbesartan—type 2 diabetes mellitus	0.000863	0.00199	CcSEcCtD
Metipranolol—Myalgia—Losartan—type 2 diabetes mellitus	0.000847	0.00195	CcSEcCtD
Metipranolol—Anxiety—Losartan—type 2 diabetes mellitus	0.000844	0.00194	CcSEcCtD
Metipranolol—Rash—Bromocriptine—type 2 diabetes mellitus	0.000839	0.00193	CcSEcCtD
Metipranolol—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000839	0.00193	CcSEcCtD
Metipranolol—Tension—Ramipril—type 2 diabetes mellitus	0.000837	0.00193	CcSEcCtD
Metipranolol—Discomfort—Losartan—type 2 diabetes mellitus	0.000837	0.00193	CcSEcCtD
Metipranolol—Headache—Bromocriptine—type 2 diabetes mellitus	0.000834	0.00192	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000833	0.00192	CcSEcCtD
Metipranolol—Nervousness—Ramipril—type 2 diabetes mellitus	0.000829	0.00191	CcSEcCtD
Metipranolol—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000815	0.00188	CcSEcCtD
Metipranolol—Somnolence—Metformin—type 2 diabetes mellitus	0.000813	0.00187	CcSEcCtD
Metipranolol—Oedema—Losartan—type 2 diabetes mellitus	0.000812	0.00187	CcSEcCtD
Metipranolol—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000805	0.00185	CcSEcCtD
Metipranolol—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000791	0.00182	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000786	0.00181	CcSEcCtD
Metipranolol—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000784	0.00181	CcSEcCtD
Metipranolol—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000769	0.00177	CcSEcCtD
Metipranolol—Rash—Glyburide—type 2 diabetes mellitus	0.000767	0.00177	CcSEcCtD
Metipranolol—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000767	0.00177	CcSEcCtD
Metipranolol—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000767	0.00177	CcSEcCtD
Metipranolol—Headache—Glyburide—type 2 diabetes mellitus	0.000762	0.00176	CcSEcCtD
Metipranolol—Palpitations—Ramipril—type 2 diabetes mellitus	0.000754	0.00174	CcSEcCtD
Metipranolol—Cough—Ramipril—type 2 diabetes mellitus	0.000744	0.00171	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.00074	0.0017	CcSEcCtD
Metipranolol—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00074	0.0017	CcSEcCtD
Metipranolol—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000731	0.00168	CcSEcCtD
Metipranolol—Myalgia—Ramipril—type 2 diabetes mellitus	0.000726	0.00167	CcSEcCtD
Metipranolol—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000724	0.00167	CcSEcCtD
Metipranolol—Anxiety—Ramipril—type 2 diabetes mellitus	0.000724	0.00167	CcSEcCtD
Metipranolol—Nausea—Glyburide—type 2 diabetes mellitus	0.000723	0.00167	CcSEcCtD
Metipranolol—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000723	0.00166	CcSEcCtD
Metipranolol—Somnolence—Losartan—type 2 diabetes mellitus	0.000722	0.00166	CcSEcCtD
Metipranolol—Asthenia—Valsartan—type 2 diabetes mellitus	0.00072	0.00166	CcSEcCtD
Metipranolol—Discomfort—Ramipril—type 2 diabetes mellitus	0.000718	0.00165	CcSEcCtD
Metipranolol—Asthenia—Orlistat—type 2 diabetes mellitus	0.000712	0.00164	CcSEcCtD
Metipranolol—Oedema—Ramipril—type 2 diabetes mellitus	0.000696	0.0016	CcSEcCtD
Metipranolol—Rash—Gliclazide—type 2 diabetes mellitus	0.000689	0.00159	CcSEcCtD
Metipranolol—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000688	0.00159	CcSEcCtD
Metipranolol—Headache—Gliclazide—type 2 diabetes mellitus	0.000685	0.00158	CcSEcCtD
Metipranolol—Dizziness—Valsartan—type 2 diabetes mellitus	0.000664	0.00153	CcSEcCtD
Metipranolol—Dizziness—Orlistat—type 2 diabetes mellitus	0.000656	0.00151	CcSEcCtD
Metipranolol—Asthenia—Metformin—type 2 diabetes mellitus	0.000656	0.00151	CcSEcCtD
Metipranolol—Nausea—Gliclazide—type 2 diabetes mellitus	0.000649	0.0015	CcSEcCtD
Metipranolol—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000636	0.00146	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000634	0.00146	CcSEcCtD
Metipranolol—Rash—Valsartan—type 2 diabetes mellitus	0.000633	0.00146	CcSEcCtD
Metipranolol—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000632	0.00146	CcSEcCtD
Metipranolol—Headache—Valsartan—type 2 diabetes mellitus	0.000629	0.00145	CcSEcCtD
Metipranolol—Rash—Orlistat—type 2 diabetes mellitus	0.000626	0.00144	CcSEcCtD
Metipranolol—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000625	0.00144	CcSEcCtD
Metipranolol—Headache—Orlistat—type 2 diabetes mellitus	0.000621	0.00143	CcSEcCtD
Metipranolol—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000621	0.00143	CcSEcCtD
Metipranolol—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000619	0.00143	CcSEcCtD
Metipranolol—Somnolence—Ramipril—type 2 diabetes mellitus	0.000619	0.00143	CcSEcCtD
Metipranolol—Dizziness—Metformin—type 2 diabetes mellitus	0.000605	0.00139	CcSEcCtD
Metipranolol—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000598	0.00138	CcSEcCtD
Metipranolol—Nausea—Valsartan—type 2 diabetes mellitus	0.000596	0.00137	CcSEcCtD
Metipranolol—Nausea—Orlistat—type 2 diabetes mellitus	0.000589	0.00136	CcSEcCtD
Metipranolol—Asthenia—Losartan—type 2 diabetes mellitus	0.000583	0.00134	CcSEcCtD
Metipranolol—Rash—Metformin—type 2 diabetes mellitus	0.000576	0.00133	CcSEcCtD
Metipranolol—Dermatitis—Metformin—type 2 diabetes mellitus	0.000576	0.00133	CcSEcCtD
Metipranolol—Headache—Metformin—type 2 diabetes mellitus	0.000573	0.00132	CcSEcCtD
Metipranolol—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000571	0.00131	CcSEcCtD
Metipranolol—Rash—Irbesartan—type 2 diabetes mellitus	0.000544	0.00125	CcSEcCtD
Metipranolol—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000544	0.00125	CcSEcCtD
Metipranolol—Nausea—Metformin—type 2 diabetes mellitus	0.000543	0.00125	CcSEcCtD
Metipranolol—Headache—Irbesartan—type 2 diabetes mellitus	0.000541	0.00125	CcSEcCtD
Metipranolol—Dizziness—Losartan—type 2 diabetes mellitus	0.000537	0.00124	CcSEcCtD
Metipranolol—Propranolol—CYP1A2—type 2 diabetes mellitus	0.000529	0.0573	CrCbGaD
Metipranolol—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.000513	0.00118	CcSEcCtD
Metipranolol—Nausea—Irbesartan—type 2 diabetes mellitus	0.000512	0.00118	CcSEcCtD
Metipranolol—Rash—Losartan—type 2 diabetes mellitus	0.000512	0.00118	CcSEcCtD
Metipranolol—Dermatitis—Losartan—type 2 diabetes mellitus	0.000511	0.00118	CcSEcCtD
Metipranolol—Headache—Losartan—type 2 diabetes mellitus	0.000509	0.00117	CcSEcCtD
Metipranolol—Asthenia—Ramipril—type 2 diabetes mellitus	0.0005	0.00115	CcSEcCtD
Metipranolol—Nausea—Losartan—type 2 diabetes mellitus	0.000482	0.00111	CcSEcCtD
Metipranolol—Dizziness—Ramipril—type 2 diabetes mellitus	0.00046	0.00106	CcSEcCtD
Metipranolol—Rash—Ramipril—type 2 diabetes mellitus	0.000439	0.00101	CcSEcCtD
Metipranolol—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000439	0.00101	CcSEcCtD
Metipranolol—Headache—Ramipril—type 2 diabetes mellitus	0.000436	0.001	CcSEcCtD
Metipranolol—Nausea—Ramipril—type 2 diabetes mellitus	0.000414	0.000953	CcSEcCtD
Metipranolol—Propranolol—CYP3A4—type 2 diabetes mellitus	0.00035	0.0379	CrCbGaD
Metipranolol—ADRB1—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	0.000129	0.000798	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—C3—type 2 diabetes mellitus	0.000128	0.000787	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	0.000127	0.000786	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	0.000127	0.000781	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GIPR—type 2 diabetes mellitus	0.000125	0.000773	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GRK5—type 2 diabetes mellitus	0.000125	0.000773	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	0.000124	0.000765	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—AGT—type 2 diabetes mellitus	0.000124	0.000765	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GIPR—type 2 diabetes mellitus	0.000123	0.000756	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GRK5—type 2 diabetes mellitus	0.000123	0.000756	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	0.000121	0.000748	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—AGT—type 2 diabetes mellitus	0.000121	0.000748	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IAPP—type 2 diabetes mellitus	0.000121	0.000747	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	0.00012	0.000742	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IAPP—type 2 diabetes mellitus	0.000118	0.000731	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	0.000118	0.000729	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	0.000118	0.000726	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	0.000118	0.000725	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	0.000117	0.000722	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	0.000116	0.000713	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	0.000115	0.000709	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MC4R—type 2 diabetes mellitus	0.000115	0.000707	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.000115	0.000707	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	0.000115	0.000706	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.000114	0.000704	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.000113	0.000695	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.000113	0.000694	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MC4R—type 2 diabetes mellitus	0.000112	0.000692	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	0.000112	0.000691	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	0.000112	0.000688	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GIP—type 2 diabetes mellitus	0.00011	0.000681	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	0.00011	0.00068	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	0.00011	0.000679	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.000109	0.000674	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GIP—type 2 diabetes mellitus	0.000108	0.000666	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	0.000107	0.000659	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000106	0.000656	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.000105	0.000647	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.000104	0.000644	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.000104	0.000642	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	0.000104	0.000641	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.000104	0.000639	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.000103	0.000633	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LEPR—type 2 diabetes mellitus	0.000103	0.000633	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.000102	0.000631	CbGpPWpGaD
Metipranolol—ADRB1—GPCR ligand binding—CCL2—type 2 diabetes mellitus	0.000102	0.00063	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GCG—type 2 diabetes mellitus	0.000102	0.00063	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	0.000102	0.000628	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GHRL—type 2 diabetes mellitus	0.000101	0.000625	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	0.0001	0.000619	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	0.0001	0.000618	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CALCA—type 2 diabetes mellitus	0.0001	0.000617	CbGpPWpGaD
Metipranolol—ADRB2—GPCR ligand binding—CCL2—type 2 diabetes mellitus	9.99e-05	0.000616	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	9.8e-05	0.000604	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TLE4—type 2 diabetes mellitus	9.75e-05	0.000601	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TLE4—type 2 diabetes mellitus	9.53e-05	0.000588	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GCG—type 2 diabetes mellitus	9.48e-05	0.000584	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ADRB3—type 2 diabetes mellitus	9.38e-05	0.000579	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	9.32e-05	0.000575	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GCG—type 2 diabetes mellitus	9.27e-05	0.000572	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ADRB3—type 2 diabetes mellitus	9.18e-05	0.000566	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	9.12e-05	0.000562	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CRHR1—type 2 diabetes mellitus	9.06e-05	0.000559	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	8.99e-05	0.000555	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AVP—type 2 diabetes mellitus	8.87e-05	0.000547	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CRHR1—type 2 diabetes mellitus	8.86e-05	0.000547	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	8.8e-05	0.000543	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AVP—type 2 diabetes mellitus	8.68e-05	0.000535	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	8.44e-05	0.000521	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	8.36e-05	0.000516	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SPRY2—type 2 diabetes mellitus	8.29e-05	0.000511	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	8.29e-05	0.000511	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	8.26e-05	0.000509	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	8.18e-05	0.000504	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—GNB3—type 2 diabetes mellitus	8.17e-05	0.000504	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	8.11e-05	0.0005	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SPRY2—type 2 diabetes mellitus	8.11e-05	0.0005	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RBP4—type 2 diabetes mellitus	8.08e-05	0.000498	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GLP1R—type 2 diabetes mellitus	8.08e-05	0.000498	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AVP—type 2 diabetes mellitus	8.06e-05	0.000497	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MMP3—type 2 diabetes mellitus	8.06e-05	0.000497	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	8.02e-05	0.000494	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—GNB3—type 2 diabetes mellitus	7.99e-05	0.000493	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	7.95e-05	0.00049	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RBP4—type 2 diabetes mellitus	7.9e-05	0.000487	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GLP1R—type 2 diabetes mellitus	7.9e-05	0.000487	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AVP—type 2 diabetes mellitus	7.88e-05	0.000486	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MMP3—type 2 diabetes mellitus	7.88e-05	0.000486	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	7.84e-05	0.000484	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCKAR—type 2 diabetes mellitus	7.77e-05	0.000479	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	7.66e-05	0.000473	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	7.54e-05	0.000465	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EDN1—type 2 diabetes mellitus	7.5e-05	0.000462	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	7.38e-05	0.000455	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—C3—type 2 diabetes mellitus	7.37e-05	0.000455	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	7.28e-05	0.000449	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—C3—type 2 diabetes mellitus	7.21e-05	0.000445	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	7.2e-05	0.000444	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IAPP—type 2 diabetes mellitus	7.15e-05	0.000441	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	7.12e-05	0.000439	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—INSR—type 2 diabetes mellitus	7.11e-05	0.000439	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	7.04e-05	0.000434	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	7.01e-05	0.000432	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IAPP—type 2 diabetes mellitus	7e-05	0.000432	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	6.99e-05	0.000431	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	6.98e-05	0.00043	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—INSR—type 2 diabetes mellitus	6.96e-05	0.000429	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	6.95e-05	0.000428	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	6.85e-05	0.000423	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	6.85e-05	0.000423	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	6.83e-05	0.000421	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	6.83e-05	0.000421	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	6.79e-05	0.000419	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	6.7e-05	0.000413	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—C3—type 2 diabetes mellitus	6.7e-05	0.000413	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	6.65e-05	0.00041	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—C3—type 2 diabetes mellitus	6.55e-05	0.000404	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	6.51e-05	0.000401	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	6.47e-05	0.000399	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	6.46e-05	0.000398	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	6.46e-05	0.000398	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AGT—type 2 diabetes mellitus	6.36e-05	0.000392	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	6.33e-05	0.000391	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	6.32e-05	0.00039	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	6.32e-05	0.00039	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	6.28e-05	0.000387	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	6.26e-05	0.000386	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CYBA—type 2 diabetes mellitus	6.25e-05	0.000386	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AGT—type 2 diabetes mellitus	6.22e-05	0.000384	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.15e-05	0.000379	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	6.14e-05	0.000379	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PLAT—type 2 diabetes mellitus	6.12e-05	0.000377	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GHRL—type 2 diabetes mellitus	6.12e-05	0.000377	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	6.12e-05	0.000377	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CYBA—type 2 diabetes mellitus	6.12e-05	0.000377	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CALCA—type 2 diabetes mellitus	6.05e-05	0.000373	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.01e-05	0.000371	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GHRL—type 2 diabetes mellitus	5.99e-05	0.000369	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PLAT—type 2 diabetes mellitus	5.99e-05	0.000369	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CALCA—type 2 diabetes mellitus	5.91e-05	0.000365	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	5.88e-05	0.000363	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	5.75e-05	0.000355	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	5.69e-05	0.000351	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	5.67e-05	0.00035	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GCG—type 2 diabetes mellitus	5.6e-05	0.000345	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	5.6e-05	0.000345	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	5.57e-05	0.000344	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	5.54e-05	0.000342	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.51e-05	0.00034	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.49e-05	0.000339	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GCG—type 2 diabetes mellitus	5.48e-05	0.000338	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	5.48e-05	0.000338	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.39e-05	0.000332	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.37e-05	0.000331	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.24e-05	0.000323	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.15e-05	0.000317	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.14e-05	0.000317	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.13e-05	0.000316	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.03e-05	0.000311	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.03e-05	0.00031	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.87e-05	0.0003	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.83e-05	0.000298	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.76e-05	0.000294	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AVP—type 2 diabetes mellitus	4.76e-05	0.000294	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.76e-05	0.000294	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.74e-05	0.000292	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.72e-05	0.000291	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.72e-05	0.000291	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	4.67e-05	0.000288	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.66e-05	0.000287	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AVP—type 2 diabetes mellitus	4.66e-05	0.000287	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.64e-05	0.000286	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.62e-05	0.000285	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOB—type 2 diabetes mellitus	4.6e-05	0.000284	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.58e-05	0.000283	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	4.57e-05	0.000282	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.53e-05	0.000279	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOB—type 2 diabetes mellitus	4.5e-05	0.000278	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.48e-05	0.000276	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.43e-05	0.000273	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LPL—type 2 diabetes mellitus	4.39e-05	0.000271	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.3e-05	0.000265	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LPL—type 2 diabetes mellitus	4.3e-05	0.000265	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.21e-05	0.000259	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.12e-05	0.000254	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.05e-05	0.00025	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.03e-05	0.000249	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.96e-05	0.000244	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—C3—type 2 diabetes mellitus	3.96e-05	0.000244	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—C3—type 2 diabetes mellitus	3.87e-05	0.000239	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.77e-05	0.000233	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.76e-05	0.000232	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGT—type 2 diabetes mellitus	3.76e-05	0.000232	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.7e-05	0.000228	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.69e-05	0.000228	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOE—type 2 diabetes mellitus	3.68e-05	0.000227	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LEP—type 2 diabetes mellitus	3.68e-05	0.000227	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.68e-05	0.000227	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGT—type 2 diabetes mellitus	3.68e-05	0.000227	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.64e-05	0.000224	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.61e-05	0.000223	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LEP—type 2 diabetes mellitus	3.6e-05	0.000222	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOE—type 2 diabetes mellitus	3.6e-05	0.000222	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.56e-05	0.00022	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.47e-05	0.000214	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.4e-05	0.000209	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.28e-05	0.000203	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.21e-05	0.000198	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—INS—type 2 diabetes mellitus	3.15e-05	0.000194	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.1e-05	0.000191	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—INS—type 2 diabetes mellitus	3.08e-05	0.00019	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.04e-05	0.000188	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.04e-05	0.000188	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.03e-05	0.000187	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.03e-05	0.000187	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.98e-05	0.000184	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.97e-05	0.000183	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.96e-05	0.000183	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.89e-05	0.000178	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.83e-05	0.000174	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.76e-05	0.00017	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.76e-05	0.00017	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.7e-05	0.000166	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.7e-05	0.000166	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.6e-05	0.00016	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RELA—type 2 diabetes mellitus	2.54e-05	0.000157	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.36e-05	0.000146	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.34e-05	0.000144	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.33e-05	0.000143	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.31e-05	0.000143	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.29e-05	0.000141	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.28e-05	0.00014	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.21e-05	0.000136	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.19e-05	0.000135	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.17e-05	0.000134	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.15e-05	0.000132	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.14e-05	0.000132	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.1e-05	0.00013	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.04e-05	0.000126	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SRC—type 2 diabetes mellitus	2e-05	0.000123	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.99e-05	0.000123	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.94e-05	0.00012	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.82e-05	0.000112	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.79e-05	0.00011	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.78e-05	0.00011	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.75e-05	0.000108	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.37e-05	8.48e-05	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.34e-05	8.29e-05	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.27e-05	7.82e-05	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.24e-05	7.65e-05	CbGpPWpGaD
